News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
10TV Earnings
Curis Inc. (CRIS) reported a second-quarter loss of $8.6 million, which translates to a loss of $4.02 per share. This information was generated by Automated Insights using data from Zacks Investment Research.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Curis Inc. (NASDAQ:CRIS) has priced a public offering of 3,733,334 shares of common stock and warrants at $1.50 per share, aiming to raise approximately $5.6 million. The offering includes warrants exercisable at $1.75 per share, expiring in five years, and pre-funded warrants for some …
Curis, Inc. announced the pricing of a public offering expected to generate approximately $5.6 million in gross proceeds. The offering involves the sale of 3,733,334 shares of common stock (or pre-funded warrants) and warrants to purchase an equal number of shares, priced at $1.50 …
Bank of America Corp DE reduced its stake in CRISPR Therapeutics AG by 10.4% in the first quarter, selling 113,815 shares and retaining 983,072 shares valued at $46.765 million. Institutional investors collectively own 69.2% of the company, which reported a quarterly loss of $0.94 …
CRISPR Therapeutics (CRSP) stock has seen a significant decline over the past five years but now appears to be fairly valued. Despite promising allogeneic CAR-T programs, its Price-to-Book ratio is in line with the biotech industry average, suggesting investors acknowledge its potential without pricing …
CRISPR Therapeutics AG's Chief Financial Officer, Prasad Raju, reported a bona fide gift of 750 Common Shares on August 7, 2026. This transaction is classified as a disposition, and following the gift, Raju directly holds 14,815 Common Shares. The Form 4 filing indicates the …
This article provides an analyst report from Morningstar on CRISPR Therapeutics AG (CRSP), noting that its gene-editing therapy Casgevy is gaining traction despite initial commercial hurdles. The report highlights the company's focus on CRISPR/Cas9-based therapeutics. It also includes various market data and related analyst …
Quantinno Capital Management LP significantly increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 613.5% in the first quarter, now owning 47,989 shares valued at $2.28 million. Institutional investors hold 69.2% of the company, and analysts maintain a "Moderate Buy" rating with an average …
Curis, Inc. is initiating a best-efforts offering of common stock and warrants to raise approximately $13.6 million for research and development of its lead candidate, emavusertib, and for working capital. The company reported $15.0 million in cash and equivalents as of March 31, 2026, …
CRISPR Therapeutics (CRSP) reported improved Q2 2026 results with higher revenue and a reduced net loss, leading to a short-term stock rebound. Despite mixed long-term performance, a discounted cash flow (DCF) model suggests the stock is significantly undervalued at $53.52 compared to a fair …
Wall Street Zen has upgraded CRISPR Therapeutics (CRSP) from a "Sell" to a "Hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average target price of $68.06. Despite a recent 3.6% increase in share price, the company reported a quarterly …
This article provides current stock news for Curis Inc (CRIS), detailing its recent stock performance, market capitalization, and links to financial data and analysis tools on TradingKey. It also indicates that more news will be available soon.
This article provides an earnings forecast for Curis Inc (CRIS), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 4 analysts, the stock has a "Buy" trend with a target price of $17.00. The report also includes past EPS …
Goldman Sachs has reiterated a Hold rating for Crispr Therapeutics AG (CRSP) with a price target of $55.00. This follows similar Hold ratings from other analysts like Wells Fargo, though H.C. Wainwright maintained a Buy rating. The company recently reported quarterly revenue of $10.18 …
Dimensional Fund Advisors LP significantly reduced its stake in CRISPR Therapeutics AG by 45.5% in the first quarter, selling 412,889 shares. Following the sale, the firm now owns 494,218 shares valued at $23.49 million. The article also covers recent analyst ratings, insider trading activity, …
This Yahoo Finance page provides a detailed overview of Curis, Inc. (CRIS) stock, including real-time price, historical data, financial statistics, and news. It highlights the company's biotechnology focus on developing drug candidates for human cancers and its collaborations. The stock showed a significant decline …
CRISPR Therapeutics (CRSP) saw its stock rise by 11.6% following its second-quarter 2026 results, which included an increase in revenue to US$10.18 million, a narrowed net loss, and the expansion of CASGEVY's FDA approval to younger children. The company also announced new in vivo …
CRISPR Therapeutics AG (NASDAQ:CRSP) reported strong second-quarter revenues of US$10m, significantly beating estimates, and a smaller-than-expected statutory loss. Following these results, analysts have substantially increased revenue forecasts for 2026 to US$54.4m and reduced expected losses, anticipating significant growth. Despite these upgrades, the consensus price …
Sharemaestro market context Price above Trend Line 52 weeks -9.1% · Next-week setup negative 27.8%Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. This follows similar Buy ratings from William Blair, though Morgan Stanley maintained a Hold. The company recently reported Q2 revenue of $10.18 million and …
The average 12-month price target for CRISPR Therapeutics AG (CRSP) stock has been raised to $84.39 from $83.94, based on estimates from 18 analysts. This updated target implies a potential upside of approximately 70% from its Aug. 3 closing price. The consensus rating among …
Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …
Sharemaestro market context Price above Trend Line 52 weeks -9.1% · Next-week setup negative 27.8%CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. The company's total revenues also exceeded expectations, reaching $10.2 million against an estimate of $7 million, driven by strong collaboration …
This page provides news and updates for Crispr Therapeutics (CRSP), a company focused on gene-based medicines. Recent updates include a Q2 2026 financial report showing $76 million in CASGEVY revenue and advancements in multiple clinical programs. The company also announced participation in several investor …
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago. These figures are adjusted for non-recurring items. This …
Crispr Therapeutics reported a second-quarter EPS of $-0.94, surpassing analyst estimates by $0.26, and revenue of $10.18M, which also topped the consensus estimate. Despite the strong earnings beat, the company's stock price has seen declines over the last three and twelve months. InvestingPro assesses …
The gene-editing biotech reports with medium-term performance still under pressure and volume running below its 13-week average.
CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings, reporting an adjusted loss of $0.94 per share, significantly beating analyst estimates of a $1.20 loss. The company also surpassed revenue expectations, bringing in $10.18 million against an estimated $7.45 million. Following these results, CRSP shares rose …
CRISPR Therapeutics AG (CRSP) reported Q2 revenue of $10.2 million, significantly surpassing the FactSet estimate of $7.4 million. This earnings flash highlights the company's financial performance for the second quarter and six months ended June 30, 2026. The article also mentions the company's recent …
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni, Ph.D., Chairman and …
Sharemaestro market context Price above Trend Line 52 weeks -9.1% · Next-week setup negative 27.8%Search by ticker symbol or company name and select a result to open its chart.